Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå ºÐ¼®°ú ¿¹Ãø(-2034³â) : À¯Çü, Á¦Ç°, ¼­ºñ½º, ±â¼ú, ÄÄÆ÷³ÍÆ®, ¿ëµµ, ¹èÆ÷, ÃÖÁ¾»ç¿ëÀÚ, ´Ü°è
Artificial Intelligence for Drug Discovery Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Component, Application, Deployment, End User, Stage
»óǰÄÚµå : 1699185
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 417 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,498,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 7,866,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,234,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀåÀº 2024³â 63¾ï ´Þ·¯¿¡¼­ 2034³â¿¡´Â 165¾ï ´Þ·¯·Î È®´ëÇϸç, CAGR ¾à 10.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀº ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϱâ À§ÇØ ÀǾàǰ ¿¬±¸¿¡ AI ±â¼úÀ» ÅëÇÕÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ¸Ó½Å·¯´×, µö·¯´×, µ¥ÀÌÅÍ ºÐ¼®À» Ȱ¿ëÇÏ¿© Ç¥Àû ½Äº°, ºÐÀÚ ½ºÅ©¸®´×, ¿¹Ãø ¸ðµ¨¸µÀ» °­È­ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ ½Å¾à°³¹ß ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó AI ±â¹Ý Ç÷§ÆûÀÇ ¹ßÀüÀÌ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ÇÏÀÌÅ×Å© ±â¾÷°ú Á¦¾à»ç °£ÀÇ Çù¾÷À» ÃËÁøÇϰí, AI µµÀÔÀ» À§ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ¸¶·ÃµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä

½Å¾à°³¹ßÀÇ ÀΰøÁö´É ½ÃÀåÀº ºü¸£°Ô ¹ßÀüÇϰí ÀÖÀ¸¸ç, ÁÖ·Î ¾à¹° ÃÖÀûÈ­ ¹× Àç»ç¿ë, ÀüÀÓ»ó °Ë»ç, ÀÓ»ó °Ë»ç ¼³°è·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áß ¾à¹° ÃÖÀûÈ­ ¹× Àç»ç¿ëÀº ºñ¿ë È¿À²ÀûÀÌ°í ½Ã°£ È¿À²ÀûÀÎ ¾à¹° °³¹ß ÇÁ·Î¼¼½ºÀÇ Çʿ伺¿¡ ÀÇÇØ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¿ìÀ§´Â ¾àÈ¿ ¿¹ÃøÀÇ Á¤È®¼ºÀ» ³ôÀÌ°í »õ·Î¿î Ä¡·á¹ý ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϱâ À§ÇØ ¾÷°è°¡ AI¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¸Ó½Å·¯´× ¾Ë°í¸®Áò°ú ½Å°æ¸Á°ú °°Àº ±â¼úÀÇ ¹ßÀüÀº ¹æ´ëÇÑ µ¥ÀÌÅͼ¼Æ®ÀÇ ºÐ¼®À» ¿ëÀÌÇÏ°Ô Çϰí, Á¤È®ÇÑ ¾à¹°-Ç¥Àû »óÈ£ÀÛ¿ëÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× AI ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö°ú °°Àº »õ·Î¿î ÇÏÀ§ ºÎ¹®ÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÏÀ§ ºÐ¾ß´Â ȯÀÚ ¸ÂÃãÇü Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í Ä¡·á °³ÀÔÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãų °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÌ ¼º¼÷ÇØÁü¿¡ µû¶ó ½Å¾à °³¹ß ¼º°ø·üÀÌ Çâ»óµÇ°í ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼ÇÀÇ Çõ½ÅÀÌ ÃËÁøµÇ¾î ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çü ÀúºÐÀÚ, »ý¹°Á¦Á¦, ¹é½Å, ÆéƼµå, Ç×ü, Ç×ü, ÇÙ»ê
Á¦Ç°¼Ò°³ ¼ÒÇÁÆ®¿þ¾î, Ç÷§Æû, Åø, µ¥ÀÌÅͺ£À̽º, µ¥ÀÌÅͺ£À̽º
¼­ºñ½º ÄÁ¼³ÆÃ, ±¸Çö, ÅëÇÕ, À¯Áöº¸¼ö, ±³À°, Áö¿ø, ÄÁ¼³ÆÃ, ±¸Çö, ÅëÇÕ, À¯Áöº¸¼ö, ±³À°, Áö¿ø
±â¼ú ¸Ó½Å·¯´×,µö·¯´×,ÀÚ¿¬ ¾ð¾î ó¸®,ÄÄÇ»ÅÍ ºñÀü,ÄÄÇ»ÅÍ ºñÀü
±¸¼º ¿ä¼Ò Çϵå¿þ¾î, ¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º
¿ëµµ Ÿ±ê ¹ß±¼, ºÐÀÚ ½ºÅ©¸®´×, ¸®µå ÃÖÀûÈ­, ÀüÀÓ»ó, ÀÓ»ó °Ë»ç, ÀÓ»ó °Ë»ç
Àü°³ Ŭ¶ó¿ìµå ±â¹Ý, ¿ÂÇÁ·¹¹Ì½º, ÇÏÀ̺긮µå
ÃÖÁ¾»ç¿ëÀÚ Á¦¾àȸ»ç, »ý¸í°øÇбâ¾÷, ¿¬±¸±â°ü, °³¹ß¾÷¹« ¼öʱâ°ü
´Ü°è ½Å¾à°³¹ß,ÀüÀÓ»ó,ÀÓ»ó,½ÂÀÎ

¸Ó½Å·¯´× Ç÷§Æû°ú ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº º¸´Ù È¿À²ÀûÀÎ ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ½Å¾à °³¹ß ºÐ¾ßÀÇ ÀΰøÁö´É ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰÀÇ È¿´ÉÀ» ³ôÀÌ°í ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϱâ À§ÇØ Á¦¾à ºÎ¹®ÀÌ AI ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ´Â °Íµµ ÀÌ·¯ÇÑ Ãß¼¼¸¦ ´õ¿í ºÎÃß±â°í ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½Å¾à °³¹ß¿¡ AI¸¦ µµÀÔÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, À¯·´°ú ¾Æ½Ã¾ÆÅÂÆò¾çÀº AI ±â¹Ý ÀÇ·á Çõ½Å¿¡ ´ëÇÑ »ó´çÇÑ ¹ßÀü°ú ÅõÀÚ¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ±¸±Û, ¸¶ÀÌÅ©·Î¼ÒÇÁÆ®, IBM°ú °°Àº ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÌ Á¸ÀçÇϰí ÀÖÀ¸¸ç, À̵éÀº °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´ µî Áö¿ªÀÇ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ƯÈ÷ ȯÀÚ ¾ÈÀüÀ» º¸ÀåÇϸ鼭 Çõ½ÅÀ» Àå·ÁÇÏ´Â Á¶Ä¡¸¦ ÅëÇØ ½ÃÀå ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½Å¾à °³¹ß¿¡¼­ AIÀÇ ¹Ì·¡´Â À¯¸ÁÇϸç, AI ¾Ë°í¸®Áò°ú ÄÄÇ»ÆÃ ¼º´ÉÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¼ºÀåÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á¿Í AI ¸ðµ¨¿¡ ´ëÇÑ °­·ÂÇÑ °ËÁõÀÇ Çʿ伺Àº ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí AI¿Í ¾çÀÚ ÄÄÇ»ÆÃ°ú °°Àº ½Å±â¼úÀÇ ÅëÇÕÀº ½Å¾à°³¹ßÀÇ »õ·Î¿î ÁöÆòÀ» ¿­°í ½ÃÀå È®´ëÀÇ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

½Å¾à°³¹ß ºÐ¾ßÀÇ ÀΰøÁö´É ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀο¡ ÀÇÇØ Å« ¼ºÀåÀ» ´Þ¼ºÇϰí ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ µ¿ÇâÀº AI¿Í ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¾î º¸´Ù Á¤È®ÇÑ ½Å¾à °³¹ß ÇÁ·Î¼¼½º°¡ °¡´ÉÇØÁ³½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº º¹ÀâÇÑ »ý¹°ÇÐÀû µ¥ÀÌÅͼ¼Æ®¿¡ ´ëÇÑ ºÐ¼® ´É·ÂÀ» °­È­ÇÏ¿© ÀáÀçÀûÀÎ ÀǾàǰ Èĺ¸¹°ÁúÀÇ ½Äº°À» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Ãß¼¼´Â Á¦¾àȸ»ç¿Í AI ±â¼ú ±â¾÷ °£ÀÇ Çù·Â °ü°èÀÇ È®´ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀº Çõ½ÅÀ» ÃËÁøÇϰí ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, AI´Â °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â°Ô Ä¡·á¸¦ Á¶Á¤ÇÔÀ¸·Î½á À̸¦ Áö¿øÇÒ ¼ö ÀÖ´Â µ¶º¸ÀûÀÎ ÀÔÁö¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Áß Çϳª´Â ±âÁ¸ ½Å¾à °³¹ß¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ë Àý°¨¿¡ ´ëÇÑ Àý½ÇÇÑ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖÀ¸¸ç, AI´Â ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí È¿À²¼ºÀ» Çâ»ó½ÃÅ´À¸·Î½á ±× ÇØ°áÃ¥À» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ »õ·Ó°í È¿°úÀûÀÎ Ä¡·á¹ý °³¹ßÀÌ ÇÊ¿äÇØÁö¸é¼­ ½Å¾à°³¹ß¿¡ AIÀÇ µµÀÔÀÌ ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¢ ±â°üµéÀÌ AI°¡ ÀǾàǰ °³¹ßÀ» º¯È­½Ãų ¼ö ÀÖ´Â °¡´É¼ºÀ» ÀνÄÇÏ°í ±ÔÁ¦ ȯ°æµµ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

¾ïÁ¦¿Í °úÁ¦

ÀΰøÁö´É ½Å¾à°³¹ß ½ÃÀå¿¡´Â ¸î °¡Áö Áß¿äÇÑ Á¦¾à¿äÀΰú °úÁ¦°¡ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦´Â AI ±â¼úÀ» ±âÁ¸ Á¦¾à ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ´Â °ÍÀε¥, À̸¦ À§Çؼ­´Â ¸¹Àº ½Ã°£°ú ¸®¼Ò½º¸¦ ÅõÀÚÇØ¾ß ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ AI¸¦ Ȱ¿ëÇÑ ½Å¾à°³¹ß ÅøÀÇ ½ÂÀÎ ÀýÂ÷°¡ ±æ°í º¹ÀâÇϹǷΠ±ÔÁ¦Àû Àå¾Ö¹°µµ Å« À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ AI ¼Ö·ç¼Ç °³¹ß ¹× µµÀÔ°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº Áß¼Ò±â¾÷ ½ÃÀå ÁøÀÔÀ» ÁÖÀúÇÏ°Ô ¸¸µé ¼ö ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦·Î ÀÎÇØ °­·ÂÇÑ º¸¾È Á¶Ä¡°¡ ÇÊ¿äÇϰí, ƯÈ÷ ȯÀÚ µ¥ÀÌÅÍ¿Í °ü·ÃµÈ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦µµ Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î AI ±â¼ú°ú Á¦¾à ÀÀ¿ëÀÇ °£±ØÀ» È¿°úÀûÀ¸·Î ¸Þ¿ï ¼ö ÀÖ´Â ¼÷·ÃµÈ Àü¹®°¡°¡ ºÎÁ·ÇÏ¿© ±â¼ú Çõ½ÅÀÇ ¼Óµµ¸¦ Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº »ê¾÷À» º¯È­½Ãų ¼ö ÀÖ´Â À¯¸ÁÇÑ ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ½Å¾à°³¹ß¿¡¼­ ÀΰøÁö´ÉÀÇ ±Þ¼ÓÇÑ Ã¤Åðú È®ÀåÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®

Á¦4Àå Drug Discovery¿ë ÀΰøÁö´É(AI) Àü¸Á

Á¦5Àå Drug Discovery¿ë ÀΰøÁö´É(AI) Àü·«

Á¦6Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå ±Ô¸ð

Á¦7Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : À¯Çüº°

Á¦8Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : Á¦Ç°º°

Á¦9Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ±â¼úº°

Á¦11Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦12Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ¿ëµµº°

Á¦13Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ¹èÆ÷º°

Á¦14Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦15Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : ´Ü°èº°

Á¦16Àå Drug Discovery¿ë ÀΰøÁö´É(AI) ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Artificial Intelligence for Drug Discovery Market is anticipated to expand from $6.3 billion in 2024 to $16.5 billion by 2034, growing at a CAGR of approximately 10.1%. The market encompasses the integration of AI technologies in pharmaceutical research, aiming to streamline drug development processes. This market focuses on leveraging machine learning, deep learning, and data analytics to enhance target identification, molecular screening, and predictive modeling. The growing need for cost-effective and efficient drug discovery solutions is propelling advancements in AI-driven platforms, fostering collaborations between tech firms and pharmaceutical companies, and encouraging regulatory frameworks for AI adoption.

Market Overview:

The Artificial Intelligence for Drug Discovery Market is evolving rapidly, segmented primarily into drug optimization and repurposing, preclinical testing, and clinical trial design. Of these, drug optimization and repurposing lead the market, driven by the need for cost-effective and time-efficient drug development processes. This segment's dominance is attributed to the industry's growing reliance on AI to enhance the accuracy of drug efficacy predictions and reduce the time-to-market for new therapies. Technological advancements, such as machine learning algorithms and neural networks, facilitate the analysis of vast datasets, enabling precise drug-target interactions. Emerging sub-segments, like personalized medicine and AI-driven biomarker discovery, are gaining traction. These sub-segments promise to revolutionize patient-specific treatments and enhance the precision of therapeutic interventions. As these technologies mature, they are expected to significantly impact the market by improving the success rates of drug discovery and fostering innovation in personalized healthcare solutions.

Market Segmentation
TypeSmall Molecule, Biologics, Vaccines, Peptides, Antibodies, Nucleic Acids
ProductSoftware, Platform, Tools, Databases
ServicesConsulting, Implementation, Integration, Maintenance, Training, Support
TechnologyMachine Learning, Deep Learning, Natural Language Processing, Computer Vision
ComponentHardware, Software, Services
ApplicationTarget Identification, Molecule Screening, Lead Optimization, Preclinical Testing, Clinical Trials
DeploymentCloud-Based, On-Premise, Hybrid
End UserPharmaceutical Companies, Biotechnology Firms, Research Institutes, Contract Research Organizations
StageDiscovery, Preclinical, Clinical, Approval

Machine learning platforms and software solutions dominate the artificial intelligence for drug discovery market, propelled by the increasing demand for more efficient drug development processes. The pharmaceutical sector's growing reliance on AI technologies to enhance drug efficacy and reduce time-to-market further bolsters this trend. Geographically, North America leads in AI adoption within drug discovery, while Europe and Asia-Pacific are witnessing significant advancements and investments in AI-driven healthcare innovations. The competitive landscape is marked by the presence of key players such as Google, Microsoft, and IBM, who are continually innovating to maintain their competitive edge. Regulatory frameworks in regions like North America and Europe are pivotal in shaping the market dynamics, particularly through policies that encourage innovation while ensuring patient safety. The future of AI in drug discovery is promising, with projections indicating accelerated growth driven by advancements in AI algorithms and computational power. However, challenges such as data privacy concerns and the need for robust validation of AI models persist. Despite these hurdles, the integration of AI with emerging technologies like quantum computing is expected to unlock new frontiers in drug discovery, presenting lucrative opportunities for market expansion.

Geographical Overview:

The Artificial Intelligence for Drug Discovery market is witnessing robust growth across various regions, each exhibiting unique characteristics. North America leads the charge, buoyed by substantial investments in AI technologies and a strong pharmaceutical sector. The presence of key industry players and academic institutions accelerates innovation, making the region a powerhouse in AI-driven drug discovery. Europe follows as a formidable contender, with its commitment to cutting-edge research and development. The region's stringent regulatory framework ensures high-quality outcomes, fostering trust and reliability in AI applications for drug discovery. Collaborative efforts between public and private sectors further bolster Europe's position. In Asia Pacific, the market is expanding rapidly, propelled by significant technological advancements and a burgeoning healthcare sector. Countries like China and India are investing heavily in AI initiatives, aiming to revolutionize drug discovery processes. This surge is supported by government policies and a growing pool of skilled professionals. Latin America is emerging as a promising market, with increasing investments in AI infrastructure and a focus on innovative healthcare solutions. The region's potential is being unlocked through strategic partnerships and government support, paving the way for future growth. The Middle East & Africa are recognizing the transformative power of AI in drug discovery. Investments in AI technologies are on the rise, driven by the need to enhance healthcare outcomes and foster economic development. These regions are poised to capitalize on AI's capabilities to address local healthcare challenges.

Recent Development:

The Artificial Intelligence for Drug Discovery Market has witnessed significant developments over the past three months. Firstly, Pfizer announced a strategic partnership with a leading AI firm to accelerate its drug discovery processes, highlighting the growing trend of pharmaceutical companies integrating AI technologies. Secondly, Roche entered into a joint venture with an AI start-up, focusing on leveraging machine learning to identify novel drug candidates, aiming to streamline and enhance their R&D efforts. Thirdly, AstraZeneca reported a major breakthrough using AI algorithms in identifying potential treatments for rare diseases, underscoring the transformative potential of AI in addressing unmet medical needs. Fourthly, a significant merger was announced between two AI-driven biotech firms, creating a powerhouse poised to innovate in the drug discovery space. Lastly, regulatory bodies in the European Union introduced new guidelines to ensure ethical AI use in drug discovery, emphasizing the importance of transparency and accountability in this burgeoning field. These developments underscore the dynamic and rapidly evolving nature of the AI for Drug Discovery Market.

Key Trends and Drivers:

The Artificial Intelligence for Drug Discovery Market is experiencing substantial growth due to several key trends and drivers. A significant trend is the increasing integration of AI with big data analytics, enabling more precise drug discovery processes. This integration is enhancing the ability to analyze complex biological data sets, thereby accelerating the identification of potential drug candidates. Another trend is the growing collaboration between pharmaceutical companies and AI technology firms. These partnerships are fostering innovation and speeding up the drug development pipeline. Additionally, there is a rising demand for personalized medicine, which AI is uniquely positioned to support by tailoring treatments to individual genetic profiles. Drivers of this market include the urgent need to reduce the time and cost associated with traditional drug discovery methods. AI offers a solution by streamlining processes and improving efficiency. Furthermore, the increasing prevalence of chronic diseases necessitates the development of new and effective therapies, further propelling the adoption of AI in drug discovery. The regulatory environment is also becoming more favorable, with agencies recognizing the potential of AI to transform drug development.

Restraints and Challenges:

The Artificial Intelligence for Drug Discovery Market encounters several critical restraints and challenges. A primary challenge is the integration of AI technologies into existing pharmaceutical workflows, which often requires substantial time and resource investment. Regulatory hurdles also pose significant barriers, as the approval processes for AI-driven drug discovery tools can be lengthy and complex. Furthermore, the high costs associated with developing and implementing AI solutions may deter smaller companies from entering the market. Data privacy concerns, particularly regarding patient data, present another obstacle, as stringent regulations necessitate robust security measures. Lastly, there is a shortage of skilled professionals who can effectively bridge the gap between AI technology and pharmaceutical applications, limiting the pace of innovation. These factors collectively impede the rapid adoption and expansion of AI in drug discovery, despite its promising potential to revolutionize the industry.

Key Companies:

Insilico Medicine, Exscientia, Benevolent AI, Atomwise, Recursion Pharmaceuticals, Schrodinger, Cyclica, Bio Symetrics, Verge Genomics, Xtal Pi, Deep Genomics, Valo Health, Two XAR, Numerate, Cloud Pharmaceuticals, Aria Pharmaceuticals, Path AI, Peptone, Healx, Inveni AI

Sources:

National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), National Science Foundation (NSF), U.S. Department of Health and Human Services (HHS), Health Canada, Biotechnology and Biological Sciences Research Council (BBSRC), The Francis Crick Institute, Massachusetts Institute of Technology (MIT) - Computer Science and Artificial Intelligence Laboratory (CSAIL), Stanford University - Institute for Computational and Mathematical Engineering, University of Oxford - Department of Statistics, Harvard University - Department of Biomedical Informatics, International Conference on Intelligent Systems for Molecular Biology (ISMB), Conference on Artificial Intelligence in Medicine (AIME), American Association for Cancer Research (AACR) Annual Meeting, Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition, Bio-IT World Conference & Expo

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Artificial Intelligence for Drug Discovery Overview

2: Executive Summary

3: Premium Insights on the Market

4: Artificial Intelligence for Drug Discovery Outlook

5: Artificial Intelligence for Drug Discovery Strategy

6: Artificial Intelligence for Drug Discovery Size

7: Artificial Intelligence for Drug Discovery, by Type

8: Artificial Intelligence for Drug Discovery, by Product

9: Artificial Intelligence for Drug Discovery, by Services

10: Artificial Intelligence for Drug Discovery, by Technology

11: Artificial Intelligence for Drug Discovery, by Component

12: Artificial Intelligence for Drug Discovery, by Application

13: Artificial Intelligence for Drug Discovery, by Deployment

14: Artificial Intelligence for Drug Discovery, by End User

15: Artificial Intelligence for Drug Discovery, by Stage

16: Artificial Intelligence for Drug Discovery, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â